Imidazoline binding sites and receptors in cardiovascular tissue

General Pharmacology

Volumn 32, Issue 1, 1999, Pages 17-22

  Molderings, Gerhard J ^a   Göthert, Manfred ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Agmatine; Clonidine displacing substance; Imidazoline binding sites; K(ATP) channel; Presynaptic imidazoline receptor

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 CHLORO 2 (2 IMIDAZOLIN 2 YLAMINO)ISOINDOLINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); AGANODINE; AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; ANANDAMIDE; ANTIARRHYTHMIC AGENT; CIRAZOLINE; CLONIDINE; DEXANABINOL; GUANIDINE DERIVATIVE; IDAZOXAN; IMIDAZOLINE; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I2 RECEPTOR; IMIDAZOLINE RECEPTOR; LIGAND; MOXONIDINE; POTASSIUM CHANNEL; RAUWOLSCINE; RIMONABANT;

ANTIARRHYTHMIC ACTIVITY; BINDING SITE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; CORONARY ARTERY; HEART MUSCLE CELL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW; SYMPATHETIC NERVE; SYMPATHETIC TONE; VASCULAR SMOOTH MUSCLE;

ANTI-ARRHYTHMIA AGENTS; BINDING SITES; CARDIOVASCULAR SYSTEM; GUANIDINE; HUMANS; IMIDAZOLES; LIGANDS; POTASSIUM CHANNELS; RECEPTORS, DRUG;

EID: 0345367512     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00070-6     Document Type: Review

References (53)

1. Avellar M.C.W., Markus R.P. Are imidazoline receptors involved in sympathetic neurotransmission in rat vas deferens? Gen. Pharmac. 27:1996;1273-1278.
2. Berdeu D., Gross R., Ribes G., Loubatieres-Mariani M.M., Bertrand G. Effects of imidazolines and derivates on insulin secretion and vascular resistance in perfused rat pancreas. Eur. J. Pharmac. 254:1994;119-125.
3. Berdeu D., Gross R., Puech R., Loubatieres-Mariani M.M., Betrand G. Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur. J. Pharmac. 275:1995;91-98.
4. Berdeu D., Puech R., Loubatieres-Mariani M., and Bertrand G M. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed. Eur. J. Pharmac. 308:1996;301-304.
5. Bohmann C., Schollmeyer P., Rump L.C. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn-Schmiedeberg's Arch. Pharmac. 349:1994;118-124.
6. Boucher M., Dubar M., Chassaing C., Vivet P., Duchene-Marullaz P. Cardiac electrophysiological effects of rilmenidine, a novel antihypertensive agent, in the conscious dog. comparison with clonidine Life Sci. 54:1994;381-387.
7. Boucher M., Chassaing C., Chapuy E. Cardiac electrophysiologic effects of alinidine, a specific bradycardic agent, in the conscious dog. plasma concentration-response relations J. Cardiovasc. Pharmac. 25:1995;229-233.
8. Brown C.A., Chan S.L.F., Stillings M.R., Smith S.A., Morgan N.G. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080. Br. J. Pharmac. 110:1993;1017-1022.
9. Challinor J.L., McPherson G.A. Evidence that imidazol(id)ine-and sulphonylurea-based antagonists of cromakalim act at different sites in the rat thoracic aorta. Clin. Exp. Pharmac. Physiol. 20:1993;467-475.
10. Challinor-Rogers J.L., Hay T.K.C., McPherson G.A. Comparison of the cromakalim antagonism and bradycardic actions of a series of novel alinidine analogues in the rat. Naunyn-Schmiedeberg's Arch. Phamac. 350:1994;158-166.
11. 2-adrenoceptors and imidazoline-binding sites in the control of insulin secretion. Clin. Sci. 85:1993;671-677.
12. Chun J., Dendorfer A., Raasch W., Dominiak P. Imidazoline binding sites do not modify contractility of rat heart. Naunyn-Schmiedeberg's Arch. Pharmac. 355(Suppl.; R29):1997.
13. Docherty J.R., Göthert M., Dieckhöfer C., Starke K. Effects of 4-chloro-2-(2-imidazolin-2-ylamino)-isoindoline hydrochloride (BE 6143) at pre- and postsynaptic α-adrenoceptors in rabbit aorta and pulmonary artery. Arzneim.-Forsch. 32:1982;1534-1540.
14. 1-Imidazoline receptors. definition, characterization, distribution, and transmembrane signaling Ann. N. Y. Acad. Sci. 763:1995;22-42.
15. 2-adrenoceptors and putative imidazoline receptors on rabbit heart sympathetic nerves. Naunyn-Schmiedeberg's Arch. Pharmac. 348:1993;127-133.
16. Gao Y., Gumusel B., Koves G., Prasad A., Hao Q., Hyman A., Lippton H. Agmatine. a novel endogenous vasodilator substance Life Sci. 57:1995;PL83-PL86.
17. 2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives. Naunyn-Schmiedeberg's Arch. Pharmac. 343:1991;271-282.
18. 2-Adrenoceptor-independent inhibition by imidazolines and guanidines of noradrenaline release from peripheral, but not central noradrenergic neurons. Ann. N. Y. Acad. Sci. 763:1995;405-419.
19. Guimaraes S., Paiva M.Q., Pereira O. α-Adrenoceptor-mediated prejunctional effects of chloroethylclonidine in the canine saphenous vein. J. Pharmac. Exp. Ther. 282:1997;1326-1330.
20. Ibbotson T., Edwards G., Weston A.H. Antagonism of levcromakalim by imidazoline- and guanidine-derivatives in rat portal vein. involvement of the delayed rectifier Br. J. Pharmac. 110:1993;1556-1564.
21. ATP. an inward rectifier subunit plus the sulfonylurea receptor Science. 270:1995;1166-1169.
22. Jurkiewicz N.H., Garcez do Carmo L., Hirata H., da Costa Santos W., Jurkiewicz A. Functional properties of agmatine in rat vas deferens. Eur. J. Pharmac. 307:1996;299-304.
23. ATP channels in guinea pig ventricular myocytes. Eur. J. Pharmac. 285:1995;309-312.
24. 2-adrenoceptors in the human heart. discrimination by clonidine and moxonidine Naunyn-Schmiedeberg's Arch. Pharmac. 354:1996;689-692.
25. 1-imidazoline receptor modulator moxonidine on ouabain-induced cardiac arrhythmia in guinea pigs. Ann. N.Y. Acad. Sci. 763:1995;620-633.
26. Molderings G.J. Imidazoline receptors. basic knowledge, recent advances and future prospects for therapy and diagnosis Drugs Future. 22:1997;757-772.
27. 2-imidazoline binding sites. Naunyn-Schmiedeberg's Arch. Pharmac. 351:1995;507-516.
28. Molderings G.J., Göthert M. Presynaptic imidazoline receptors mediate inhibition of noradrenaline release from sympathetic nerves in rat blood vessels. Fundam. Clin. Pharmac. in press:1998.
29. Molderings G.J., Hentrich F., Göthert M. Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery. Naunyn-Schmiedeberg's Arch. Pharmac. 344:1991;630-638.
30. 3H]-idazoxan binding sites in human cardiovascular tissues. Br. J. Pharmac. 122:1997;43-50. a.
31. Molderings G.J., Likungu J., Göthert M. Does the presynaptic imidazoline receptor (PIR) belong to the cannabinoid (CB) receptor family? Naunyn-Schmiedeberg's Arch. Pharmac. 356(Suppl. 1):1997;R50. b.
32. Monsuez J.J. Cardiac potassium currents and channels. I. basic science aspects Int. J. Cardiol. 61:1997;209-219.
33. Morrissey J.J., Klahr S. Agmatine activation of nitric oxide synthase in endothelial cells. Proc. Assoc. Am. Physicians. 109:1997;51-57.
34. Okumura K., Ichihara K., Nagasaka M. Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein. Eur. J. Pharmac. 215:1992;253-257.
35. 3H]mivazerol binding in the rat heart. Br. J. Pharmac. 122(Proc. Suppl.):1997;68P.
36. Regunathan S., Reis D.J. Imidazoline receptors and their endogenous ligands. Annu. Rev. Pharmac. Toxicol. 36:1996;511-544.
37. Regunathan S., Reis D.J. Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells. Hypertension. 30:1997;295-300.
38. Regunathan S., Youngson C., Wang H., Reis D.J. Imidazoline receptors in vascular smooth muscle and endothelial cells. Ann. N.Y. Acad. Sci. 763:1995;580-590.
39. Regunathan S., Youngson C., Raasch W., Wang H., Reis J. Imidazoline receptors and agmatine in blood vessels. a novel system inhibiting vascular smooth muscle proliferation J. Pharmac. Exp. Ther. 276:1996;1272-1282.
40. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
41. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
42. Roegel J.C., Yannoulis N., De Jong W., Monassier L., Feldman J., Bousquet P. Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan. Naunyn-Schmiedeberg's Arch. Pharmac. 354:1996;598-605.
43. 2-autoreceptors are involved in the blood pressure-lowering effect of moxonidine. J. Cardiovasc. Pharmac. 16:1990;15-22.
44. 3 receptors Neurochem. Int. 30:1997;73-83.
45. Schwanstecher M., Hasselblatt A. The imidazoline compound phentolamine stimulates insulin release in a way different from that of sulfonylureas. Naunyn-Schmiedeberg's Arch. Pharmac. 344(Suppl. 2):1991;R134.
46. + channels. Eur. J. Pharmac. 211:1992;87-95.
47. 3H]noradrenaline release in the rat anococcygeus muscle. J. Physiol. 467:1993;302P.
48. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev. Physiol. Biochem. Pharmac. 77:1977;1-124.
49. 2-autoreceptors. Rev. Physiol. Biochem. Pharmac. 107:1987;73-146.
50. Sun M.K., Regunathan S., Reis D.J. Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rat. Clin. Exp. Hypertens. 17:1995;115-128.
51. Synetos C., Manolopoulous V.G., Atlas C., Pipili-Synetos E. Human plasma-derived material with clonidine displacing substance (CDS)-like properties contracts the isolated rat aorta. J. Auton. Pharmac. 11:1991;343-352.
52. Wilde A.A.M., Veldkamp M.W., van Ginneken A.C.G., Opthof T. Phentolamine blocks ATP sensitive potassium channels in cardiac ventricular cells. Cardiovasc. Res. 28:1994;847-850.
53. Youngson C., Regunathan S., Wang H., Li G., Reis D.J. Coexpression of imidazoline receptors and agmatine in rat carotid artery. Ann. N. Y. Acad. Sci. 763:1995;440-444.